Related Experiment Videos
[Long-term therapy with a retard theophylline preparation]
Fortschritte Der Medizin
|May 10, 1995
Summary
Long-term slow-release theophylline significantly improved lung function, increasing FEV1 and PEF by up to 20% in asthma and 14% in COPD patients. The formulation
Area of Science:
- Pulmonary Medicine
- Pharmacology
Context:
- Investigating long-term therapeutic effects on respiratory conditions.
- Assessing the efficacy of slow-release theophylline formulations.
Purpose:
- To evaluate the impact of sustained-release theophylline on FEV1 and PEF.
- To determine the contribution of the galenic formulation to therapeutic outcomes.
Summary:
- A multicenter study involving 908 patients demonstrated that slow-release theophylline improved FEV1 and PEF.
- Asthma patients saw approximately 20% improvement, while COPD patients experienced 11-14% increases.
- The specific slow-release formulation enhanced theophylline's therapeutic benefits.
Impact:
- Provides evidence for the efficacy of slow-release theophylline in managing asthma and COPD.
- Highlights the importance of formulation in drug delivery and patient outcomes.
- Supports the use of optimized theophylline preparations for improved pulmonary function.